CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 860 target
Drug / intervention
hypofractionated concurrent chemoradiotherapy +1 moreradiation
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02688036
NCT02688036Phase 3Completed

Phase III Randomized Study of Hypofractionated vs Conventionally Fractionated Concurrent Chemo-radiotherapy for Limited Disease Small Cell Lung Cancer

Cancer Institute and Hospital, Chinese Academy of Medical Sciences·interventional·Posted Feb 23, 2016·Updated May 29, 2026

In Brief

A Phase 3 clinical trial evaluating hypofractionated concurrent chemoradiotherapy and conventionally fractionated concurrent chemoradiotherapy for Carcinoma, Small Cell and Lung Neoplasms. Completed, enrolled 860 participants across 1 site.

Detailed Summary

The purpose of this study is to determine whether hypofractionated concurrent chemo-radiotherapy has the same efficiency as conventionally fractionated concurrent chemo-radiotherapy in Limited Disease Small Cell Lung Cancer.

Study Details

Timeline

Phase 3CompletedFinished
20162017201820192020202120222023202420252026
First PostedFeb 23, 2016
Enrollment StartFeb 1, 2016
Primary CompletionOct 1, 2022
Study CompletionDec 1, 2023
TodayJul 2, 2026
Enrollment to primary: 6.7 yearsPosted 10.4 years ago

Interventions

hypofractionated concurrent chemoradiotherapyradiation

For patients with Limited Disease Small Cell Lung Cancer, 45Gy/15F of radiotherapy with concurrent chemotherapy will be used in experimental arm.

conventionally fractionated concurrent chemoradiotherapyradiation

For patients with Limited Disease Small Cell Lung Cancer, 60Gy/30F of radiotherapy with concurrent chemotherapy will be used in the control arm.